



---

DECEMBER 13-15, 2023  
MIAMI, FLORIDA

Dear Esteemed Doctors and Researchers,

We are deeply honored to welcome you to the inaugural Cure CRC Summit, hosted by the Colorectal Cancer Alliance. This event is the kickoff to the Alliance's Project Cure CRC initiative, which will fund tens of millions of dollars in research over the next two years. Your presence here today is not just a gathering of the finest minds, but a beacon of hope for millions around the world who are affected by this devastating disease. Each one of you represents the pinnacle of dedication, knowledge, and innovation in the field of oncology and medical research. This Summit is a unique forum where your groundbreaking work, unparalleled expertise, and visionary insights converge to forge a path towards a cure for colorectal cancer.

As we embark on this collaborative journey, remember that your relentless pursuit of knowledge and solutions has the power to alter the course of medical history. The breakthroughs and discussions that will transpire over the next few days and beyond have the potential to transform the landscape of colorectal cancer treatment and prevention. Our work together here in Miami will culminate in a robust RFP that will inspire investigators and accelerate their research.

You are the vanguards at the cutting edge of science, working tirelessly to unravel the complexities of this disease. Your work goes beyond laboratories and journals – it touches lives, restores hope, and builds a future where colorectal cancer is no longer a life-threatening condition. Let this Summit serve as a crucible for innovation and progress. Together, we stand on the cusp of monumental achievements. Your expertise, passion, and collaboration are the key drivers that will lead us towards our mission to end colorectal cancer in our lifetime.

On behalf of the Colorectal Cancer Alliance, its Board, its staff, and the millions who are affected by this disease, we thank you for your invaluable contributions and unwavering commitment to this cause.

Together, we will save lives.



Katie Chudnovsky  
Summit Co-Chair  
Alliance Board Member



Michael Sapienza  
Summit Co-Chair  
CEO, Colorectal Cancer Alliance

Name:

---

## Leadership

---

### Project Cure CRC Co-Chairs

**Michael Sapienza**  
CEO, Colorectal Cancer Alliance

**Katie Chudnovsky**  
Colorectal Cancer Alliance

---

### Alliance Board Chair

**Lee Dranikoff**  
Founder, Practical Strategy

---

### Alliance Project Lead

**David Fenstermacher, PhD**  
Senior Director of Research  
and Medical Affairs,  
Colorectal Cancer Alliance

---

### Scientific Co-Chairs

**John Marshall, MD**  
Georgetown University

**Scott Kopetz, MD, PhD, FACP**  
MD Anderson Cancer Center

**Christopher Lieu, MD**  
University of Colorado Cancer Center

---

### Patient Advocate Co-Chair

**John Woerner**  
mCRC Survivor and Board Member,  
Colorectal Cancer Alliance

## Grant Review Committee

---

**J. Randolph Hecht, MD**  
UCLA Health

**Scott Kopetz, MD, PhD, FACP**  
MD Anderson Cancer Center

**Christopher Lieu, MD**  
University of Colorado  
Cancer Center

**John Marshall, MD**  
Georgetown University

**Alan P. Venook, MD**  
UCSF Health

## Agenda

### DAY 1

**Wednesday**  
**December 13, 2023**

---

**2:00pm - 6:00pm**  
**Registration**

---

**6:00pm - 7:00pm**  
**Welcome Reception**  
*Remarks by*  
*Katie Chudnovsky*  
*and Michael Sapienza,*  
*Co-Chairs*

---

**7:00pm - 9:00pm**  
**Group Dinner**  
*Remarks by*  
*John Marshall, MD,*  
*Scott Kopetz, MD and*  
*Christopher Lieu, MD*

### DAY 2

**Thursday**  
**December 14, 2023**

---

**7:30am - 8:50am**  
**Breakfast**

---

**9:00am - 12:00pm**  
**Finding the Best**  
**Science (Plenary**  
**Session)**  
*Remarks by Amy Low,*  
*Alliance Board Member*

---

**12:00pm - 1:15pm**  
**Lunch**

---

**1:15pm - 5:15pm**  
**Breakout Sessions**

---

**5:15pm - 6:30pm**  
**Networking and**  
**Free Time**

---

**6:30pm - 9:00pm**  
**Group Dinner**  
*Remarks by*  
*John Woerner,*  
*Alliance Board Member*

### DAY 3

**Friday**  
**December 15, 2023**

---

**7:30am - 8:50am**  
**Breakfast**

---

**9:00am - 11:00am**  
**Industry Presentations**  
**(15 min. each)**

---

**11:15am - 12:15pm**  
**The Best Science**  
**Read-Out (Plenary**  
**Session)**

---

**12:15pm - 12:30pm**  
**Closing Remarks**

---

**12:30pm - 2:00pm**  
**Lunch, Networking**  
**and Departures**

---

*Note: Breaks will be*  
*interspersed throughout*  
*each day.*





Attendees



**METIN AKAY, PhD**  
Professor and Chair  
University of Houston

Dr. Metin Akay has been the Chair of the University of Houston Biomedical Engineering Department since 2010. He has developed a new cancer chip that allows multiple simultaneous drug administration and a massive parallel testing of drug response for cancer patients. The new chip generates tumor spheroids, or clusters, and provides large-scale assessments on the response of these tumor cells to various concentrations and combinations of drugs. Preliminary studies enable individuals to utilize the cancer chip to determine the optimal combination of anticancer drugs, using only a tiny tissue sample collected from a patient by biopsy. Ultimately, this technology may allow physicians to most effectively treat GBM in patients over a shorter period of time.



**ERICA K. BARNELL, MD, PhD**  
Chief Medical Officer  
Geneoscopy

Dr. Barnell, serves as the Co-Founder, Chief Medical Officer, and Chief Science Officer at Geneoscopy, a healthcare company dedicated to developing noninvasive diagnostics for monitoring, diagnosing, and treating gastrointestinal disease. At Geneoscopy, Dr. Barnell played a crucial role in the development of the ColoSense test—an RNA-based diagnostic designed for screening average-risk individuals for colorectal cancer and advanced adenomas. The ColoSense test recently demonstrated the highest sensitivity for colorectal neoplasia during its pivotal CRC-PREVENT clinical trial. Currently, the test is undergoing FDA review as a Class III medical device, showcasing its potential as an innovative and effective tool for early detection and screening in colorectal health.



**JACQUELINE BARRIENTOS, MD, MS**  
Chief of Hematologic Malignancies and Director  
of Oncology Research  
Mount Sinai Medical Center

Dr. Jacqueline C. Barrientos is a hematologist-oncologist at Mount Sinai Medical Center where she has been appointed Chief of Hematologic Malignancies and Director of Oncology Research. She is Adjunct Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Barrientos received her medical degree from the Ponce Health Sciences University where she was the recipient of two Howard Hughes Medical Institute Fellowship Awards and was elected to the Alpha Omega Alpha National Medical Honor Society. She obtained a master's degree in Clinical Investigation at the Weill Cornell Graduate School of Medical Sciences. Dr. Barrientos served as Principal Investigator on several clinical trials that led to the approval of novel therapies that changed the treatment paradigm of CLL and lymphoma.



**EDUARD BATLLE, PhD**  
Professor  
Institute for Research in Biomedicine of Barcelona  
(IRB Barcelona)

Dr. Eduard Batlle is the Director of the Cancer Science Program at IRB Barcelona (Spain). His pioneering research has uncovered an immune-suppressive TGF-beta-driven program within the tumor microenvironment of metastatic CRC. More recently, Dr. Batlle has elucidated the nature of minimal residual disease and the mechanisms that underpin metastatic relapse.



**EMMA BERRY**  
Senior Public Affairs and Advocacy Relations Manager  
Exelixis

Emma Berry is the Senior Manager for Advocacy Relations at Exelixis in Washington, DC. She has advocated for patients through disease education and awareness, as well as through policy change to support access to medicines for the past 8 years. In her role at Exelixis, she works to amplify the patient voice and manages charitable giving initiatives to support CRC patients and caregivers.



**CHRIS BRADLEY, MS**  
Chief Executive Officer and Co-Founder  
Mutagentech

Mr. Chris Bradley is a serial entrepreneur with a passion for turning powerful science into next-gen therapies and treatments for patients. He is currently the founder of Loki Therapeutics, an attenuated bacteria immune-oncology company and Mutagentech, an ultra-high resolution mutation sequencing company.





**MAKAYLA BROADFOOT**  
Patient Advocate Specialist  
Exact Sciences

Makayla Broadfoot joined Exact Sciences five years ago, marking the beginning of her professional career in the field of colorectal cancer. She has been actively engaged in advocacy, collaborating to enhance our understanding of the patient experience across all facets of colorectal cancer. Her role includes assisting patients with managing their bills related to colorectal cancer screening and contributing to policy efforts aimed at reducing barriers to access for screening for colorectal cancer.



**WILLIAM BURKE, MD**  
Vice Chairman of Radiology  
Mount Sinai Medical Center of Florida

Dr. Burke is Vice Chairman of the Radiology Department and Program Director of the Radiology Residency Program at Mount Sinai Medical Center of Florida with a clinical, educational and research focus on Cardiothoracic, Body, Nuclear Medicine and Oncologic Imaging.



**JENNIFER S. BUELL, PhD**  
President and Chief Executive Officer  
MiNK Therapeutics

Dr. Buell is the President and Chief Executive Officer at MiNK Therapeutics and the Chairman, Executive Council at Agenus. She brings more than 27 years of biopharmaceutical experience, leading teams to advance discovery candidates through to clinical development to commercialization. She was previously President and Chief Operating Officer at Agenus, where she was responsible for organizational operations, including research, clinical development, manufacturing, commercial operations, investor relations and external affairs. Prior to Agenus, Dr. Buell held leadership positions in R&D operations at Bristol-Myers Squibb and Harvard Clinical Research Institute (Baim), where she was involved in the development strategy and operations for a portfolio of industry and government-sponsored clinical programs.



**ASHLEY CALABRESE**  
Patient Advocacy Lead, Colorectal Cancer  
Takeda Oncology

Ashley Calabrese spent the first 15 years of her career at health-related non-profit advocacy organizations, first in the digestive diseases space and then transferring over to oncology, where she has been for the last 3 years. Her experience focused on working with external partners to develop collaborative relationships to advance education, support, and research programs for digestive diseases and then blood and solid tumor cancers. Most recently, she moved into an industry role where she is currently serving at the Patient Advocacy Lead for Colorectal Cancer at Takeda Oncology.



**SEAN CARRICK**  
Chief Executive Officer  
Nascent Biotech

Mr. Sean Carrick is the CEO of Nascent Biotech Inc. His experience spans over 30 years and he has held leadership roles at a variety of life sciences companies, including Pfizer, Conmed and Maquet Medical. Mr. Carrick has also been part of several start-up ventures including Praecis Pharma and Aveolus. He was directly involved in a strategic partnership with Hisun Bioray of China. In his time at Nascent, Mr. Carrick has led the development of Pritumumab from preclinical to Phase II ready and is currently exploring other therapeutic applications for PTB.



**MYRIAM CHALABI, MD, PhD**  
Medical Oncologist and Cancer Immunotherapy researcher,  
Gastrointestinal Oncology  
Netherlands Cancer Institute

Dr. Chalabi was named one of the 11 early career researchers to watch by Nature Medicine. She is the lead investigator of several neoadjuvant immunotherapy trials in gastrointestinal cancers, including the globally renowned NICHE study, in which patients with colon cancers were found to have impressive responses after a short duration of neoadjuvant immunotherapy. Her research focuses on early innovative combination immunotherapy trials with a strong focus on translational research to better understand the drivers of response in these tumors and find novel immunotherapy combinations. Her main goal is to improve immunotherapy for patients with gastrointestinal cancers.



**ANDREA CERCEK, MD**  
Gastrointestinal Oncologist  
Memorial Sloan Kettering Cancer Center

Dr. Andrea Cercek is a board-certified medical oncologist specializing in the treatment of patients with gastrointestinal (GI) cancers, particularly colorectal cancer, appendix cancer, and cholangiocarcinoma. Her research is focused on the development of novel systemic and regional therapies, including approaches based on tumor genomics, with the goal of improving outcomes while minimizing treatment-related toxicities. Dr. Cercek is the founder and co-director of the Center for Young Onset Colorectal and Gastrointestinal Cancer. This clinic — the first of its kind in the world — is dedicated solely to the specific needs of people under 50 who have CRC or other GI cancers.



**MAY CHO, MD**  
Senior Medical Director, Clinical Development  
Replimune

Dr. Cho is a gastroenterology oncologist focused on colorectal cancers. Dr. Cho treats gastrointestinal cancer patients in clinic and is also active in a variety of research. She collaborates with basic science, translation research and conducts clinical trials. Dr. Cho was an active member and chair of committees in the cancer center, co-operative groups such as SWOG and Anal Rectal NCI task force, and ASCO guideline committee. Currently, Dr. Cho is the Senior Medical Director of Replimune, an oncolytic immunotherapy company.



**YEKATERINA "KATIE" CHUDNOVSKY, JD**  
Chair of GI Research Foundation Board of Directors  
and Board of Directors Member  
Colorectal Cancer Alliance

Mrs. Yekaterina "Katie" Chudnovsky is an attorney, venture investor, dedicated patient advocate, and supporter of medical research. She is deeply committed to the cause, leading and participating in countless research projects that aim to expand our understanding of rare cancers and the most effective ways to fight them. Her philanthropic endeavors have significantly advanced the reach and resources of cancer research. Mrs. Chudnovsky serves as the chairperson of GI Research Foundation (GIRF) for the University of Chicago Digestive Diseases Center. In addition to being general counsel for an international privately-held technology firm, she serves on the Board of Directors for Elicio Therapeutics, Immix Biopharma, XCures, and the Colorectal Cancer Alliance.



**JOHN "AL" COPLAND, PhD**  
Scientist  
Mayo Clinic

Dr. Copland leads the Cancer Biology and Translational Research Laboratory at Mayo Clinic's campus in Florida. Research in the lab is aimed at better understanding the mechanisms and pathways of carcinogenesis and tumor progression in order to develop novel, synergistic cancer therapies. Discoveries from the Copland laboratory include RhoB, transforming growth factor receptor 3 (TBR3) and GATA3 as tumor suppressor genes in addition to FOXO3a, stearyl CoA desaturase 1 (SCD1), neuronal pentraxin 2 (NPTX2) and others as novel oncogenes. Focus areas include cancer, individualized medicine and new drug development.



**KRISTEN CIOMBOR, MD, MSCI**  
Associate Professor of Medicine  
Vanderbilt University Medical Center

Dr. Ciombor specializes in the treatment of patients with gastrointestinal cancers, especially CRC. Her research involves the design and implementation of clinical trials for patients with CRC, with a focus on genomically-selected therapies and translational medicine, and she has led several national investigator-initiated clinical trials in this space. She is an integral member of the Vanderbilt-Ingram Cancer Center's (VICC) Gastrointestinal Specialized Program of Research Excellence (GI SPORE), of which she is a project co-leader, the Eastern Cooperative Oncology Group (ECOG) of which she serves as the Colorectal/Anal Working Group chair, the NCI Rectal/Anal Cancer Task Force, the National Comprehensive Cancer Network's (NCCN) Colorectal/Anal/Small Bowel Guidelines Panel, the Society for Immunotherapy of Cancer (SITC) GI Cancer Immunotherapy Guideline Expert Panel, the Academic GI Cancer Consortium (AGICC), and the Academic and Community Cancer Research United (ACCRU), of which she serves on the board of directors.



**EMILY CORSE, PhD**  
Executive Vice President, Biology and Translation  
Larkspur Biosciences

Dr. Corse is committed to the development of new treatments for colorectal cancer that is possible due to new understanding of scientific connections between cancer biology and immunology. Dr. Corse's background is in cancer immunotherapy, and she has developed new treatments for cancer patients during her career in the pharmaceutical and biotech industry.





---

**MIKE CUSNIR, MD**

Chief, Division of Hematology and Oncology; Co-Director, Gastrointestinal Malignancies; Assistant Professor at the Columbia University Division of Hematology/Oncology Mount Sinai Medical Center

Dr. Cusnir earned his medical degree from Pontificia Universidad Javeriana in Colombia and completed his internal medicine residency at Maimonides Medical Center in Brooklyn, New York. He went on to complete a fellowship in hematology and oncology at University of Maryland Medical System. Since joining Mount Sinai Medical Center in 2003, Dr. Cusnir has been an active member of the gastrointestinal committee of the Alliance for clinical trials in Oncology (Formerly CALGB). He is currently the division chief of hematology and oncology and since 2010 has been the co-director of Gastrointestinal Malignancies.



---

**GISSOO DECOTIIS, MBA**

Executive Director, Global Head of Advocacy and Strategic Relations Daiichi Sankyo, Inc.

Gissou DeCotiis is the Head of Global Advocacy and Strategic Relations for Daiichi Sankyo. Her role is to help the patient voice be heard in this global organization and help build strong relationships with our patient advocates around the world while creating broad awareness of the disease with decision makers and the public. For Daiichi Sankyo, it is crucial to understand the real needs of the patients and to learn from their experiences in order to help build more relevant studies that will help patients live a longer and healthier journey. Gissou has over 30 years of experience in various industries with a master's degree in Business (Finance). She joined Daiichi Sankyo in 2018 as Sr. Director of Global Advocacy in Global Medical Affairs and has been involved with all early and late stage assets for the organization.



---

**CHERYL DAVIS**

President and Founder Red Thred Solutions

Cheryl Davis is an established leader with 25+ years of global pharmaceutical-industry experience. On that path, she learned that it is essential to hear the voices and act upon the experiences of patients—from early in the drug development cycle through to the health-care market. So, she founded Red Thred Solutions to help companies develop the practices and partnerships needed to establish long-term, mutually beneficial patient engagement programs that align stakeholders across the drug-development cycle.



---

**PETE DEMUTH, PhD**

Chief Scientific Officer Elicio Therapeutics

Dr. DeMuth is a founding scientist at Elicio and currently serves as Chief Scientific Officer, leading the development of technology platforms for cancer immunotherapeutics from early research to clinical development. To this role, he brings over 15 years of experience in oncology, immunology and materials science. Prior to joining Elicio, Dr. DeMuth oversaw efforts to develop novel technologies for immunotherapy and vaccine development at the Massachusetts Institute of Technology's Koch Institute for Integrative Cancer Research in affiliation with the Ragon Institute of Massachusetts General Hospital, MIT, and Harvard University, where he received recognition from the National Institutes of Health and the American Chemical Society.



**LUIS DIAZ, MD**  
Physician Scientist  
Memorial Sloan Kettering Cancer Center

Dr. Diaz is a physician-scientist who leads the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center. His team pioneered the use of circulating tumor DNA as a cancer screening, monitoring, and detection of occult disease; and also discovered the therapeutic link between genetics and immunotherapy in patients with mismatch repair deficient tumors. This research led to the first tumor agnostic FDA approval and the first cancer study that resulted in a 100% complete remission rate. He is a member of the National Academy of Medicine and in 2021, Dr. Diaz was appointed by President Biden to the National Cancer Advisory Board.



**LEE DRANIKOFF, JD, MA**  
Founder, Practical Strategy and  
Colorectal Cancer Alliance Board Chair

Mr. Lee Dranikoff is the current Chair of the Board of the Colorectal Cancer Alliance. Professionally, Lee is the founder of Practical Strategy, a boutique consulting firm primarily working with private equity firms and their portfolio companies. Prior to that, Mr. Dranikoff was a Managing Director at American Securities where he helped build and lead the American Securities Resources Group. He started his business career at McKinsey & Co. In addition to his work with the Colorectal Cancer Alliance, Mr. Dranikoff is the Board Chair of Hillel International and a member of the Board of Full Bloom.



**BOB DONOVAN**  
Director, Advocacy and Professional Relations  
Pfizer Oncology

Mr. Bob Donovan has over 30 years in the Pharmaceutical industry and has spent the last 14 years working with Patient Advocacy groups in the Lung and RCC cancer space and has spent the last several years involved with the CRC and Melanoma patient community. He has recently relocated to St. Petersburg Florida from the Philadelphia area.



**MARK ERLANDER, PhD**  
Chief Executive Officer  
Cardiff Oncology, Inc.

Dr. Erlander has served as Chief Executive Officer since May 2020 and formerly as the Chief Scientific Officer from March 2013 to May 2020. Previously, he was Chief Scientific Officer at bioTheragnostics, a molecular diagnostic testing company focused on clinical applications in oncology, where he served from 2008 to 2013. From 2000 to 2008, Dr. Erlander was Chief Scientific Officer at Arcturus, Inc. (later AviraDx), which was acquired by bioMérieux in 2008. Dr. Erlander entered therapeutics as a Group Leader and then Research Fellow in drug discovery at Johnson & Johnson from 1994 to 2000. He has 44 issued patents, over 50 pending applications, and has co-authored more than 90 scientific publications.



---

**DAVID FENSTERMACHER, PhD**

Senior Director of Research and Medical Affairs  
Colorectal Cancer Alliance

Dr. David Fenstermacher has more than 30 years of research experience as a molecular biologist, geneticist and bioinformaticist in academia and industry. The latter half of Dr. Fenstermacher's career focused on designing and leading the implementation of numerous bioinformatics and biomedical informatics distributed computing systems to support basic, translational, and clinical research. Other projects included developing informatics resources to support precision medicine, drug discovery and development, FAIR Data architectures, genomics, and digital health.



---

**YUMAN FONG, MD**

Surgical Oncologist  
City of Hope

A pioneer both in the operating room and in the laboratory, Yuman Fong, M.D., The Sangiacomo Family Chair in Surgical Oncology and chair of the Department of Surgery is an internationally recognized expert in cancers of the liver, pancreas, gallbladder and bile ducts. He has led the research effort to employ genetically modified viruses to destroy cancer cells. Dr. Fong joined City of Hope in 2014 after more than two decades at the renowned Memorial Sloan-Kettering Cancer Center in New York City. Dr. Fong is both author and innovator: He has developed many new surgical techniques and instruments and written and edited hundreds of scholarly articles as well as nearly a dozen textbooks.



---

**JASON FLEMING, MD, FACS**

Chair and Senior Member  
of the Department of Gastrointestinal Oncology  
Moffitt Cancer Center

Dr. Jason Fleming is Chair and Senior Member of the Department of Gastrointestinal Oncology. Dr. Fleming is also a member of the Chemical Biology and Molecular Medicine Program. Prior to coming to Moffitt, Dr. Fleming was professor with tenure in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center in Houston, where he served as chief of Pancreas Surgery and executive director of Perioperative Services. Dr. Fleming was co-director of the Pancreatic Cancer Moonshot Program, a Scientific and Medical Advisory board member for the Pancreatic Cancer Action Network (PanCAN), and a consultant for the Society of Abdominal Radiology Disease-Focused Panel. He has been recognized for his outstanding research publications, and in 2016 he received the President's Faculty Recognition Award for Outstanding Contribution to the University of Texas MD Anderson Cancer Center.



---

**ALISON KIEHL FRIEDMAN**

Founder, Social Justice Spirits  
and Patient Advocate

Alison Kiehl Friedman is a founder of 1953 Tequila, the first ultra premium tequila founded, farmed, distilled and led by women. As the former CEO of the International Corporate Accountability Roundtable (ICAR), she has deep experience in social justice supply chain management, having helped to reform the world's largest supply chain to better protect workers within it and craft legislation that improved human rights transparency and accountability within a global economy. She has led numerous nonprofits, served as a diplomat in the Obama Administration, and recently ran for Congress in Northern Virginia. In January of 2023, she was diagnosed with stage IV adenocarcinoma of the ascending colon, BRAF V600E, intact MMR, TMB-L s/p.



**MARCO GERLINGER, MD, FRCP**

Professor of Gastrointestinal Cancer Medicine;  
Consultant Medical Oncologist and Director of GI Cancer  
Research at St. Bartholomew's Hospital  
Barts Cancer Institute and St. Bartholomew's Hospital

Dr. Marco Gerlinger is a GI Medical Oncologist and Clinician Scientist at St Bartholomew's Hospital in London, UK. His main areas of interest in CRC are how we can make immunotherapy work in MMRp CRCs, how drug resistance evolves, and how we can treat early-stage CRCs more effectively through precision medicine technologies.



**CLAUDIA GRAVEKAMP, PhD**

Associate Professor  
Albert Einstein College of Medicine,  
Department of Microbiology and Immunology

Dr. Gravekamp's laboratory develops and tests immunotherapies that are highly effective against metastatic cancer in mice. This involves selective delivery of antigens to the tumor site and inside tumor cells that function as a recall antigen (exposed to earlier in life) and as neoantigen surrogate (highly immunogenic), attracting and activating T cells, using an attenuated non-pathogenic bacterium *Listeria monocytogenes*. Cancers that have been tested are pancreatic, ovarian and colorectal cancer. Currently, she is preparing for a phase I clinical trial with pancreatic cancer.



**JACK GIERLICH**

Leal Health  
Head of Marketing

Mr. Gierlich is currently the Head of Marketing for Leal, a tech start-up using AI to clinically match cancer patients to clinical trials, and empower them to take action. While at Leal, they've been able to craft unique high-converting personalized journeys, demonstrate growth of over 15% a month, lead a growing team, and help impact and empower tens of thousands in the midst of their cancer journeys.



**JOE GROSSMAN, MD**

Vice President Early Stage Clinical Development  
Agenus, Inc.

Dr. Grossman is the Vice President of Early-Stage Clinical Development at Agenus where he leads the development of botensilimab, a multifunctional Fc-enhanced CTLA-4 antibody designed to treat immunologically "cold" tumors and directs the company's CRC and pancreatic clinical studies. He came to Agenus in 2020 from Beth Israel Deaconess Medical Center/Harvard Medical School where he was a GI oncologist treating patients, and led clinical trials and translational research in colorectal cancer and other GI malignancies. At Agenus, it has been the highlight of his career to begin to show that immunotherapy can not only potentially work in MSS CRC but may also lead to deep and durable responses for patients who have exhausted standard treatment options. Dr. Grossman also has a family member being treated for young onset colorectal cancer and is looking forward to working together towards a future where all CRC patients can be cured.





**JUSTIN GUINNEY, PhD**  
Senior Vice President of Cancer Genomics  
Tempus Labs

Dr. Guinney is SVP of Cancer Genomics Research at Tempus Labs. Trained as a computational biologist with a specialization in machine learning and cancer genomics, he currently leads a team of data scientists and bioinformaticians that use Tempus' large clinicogenomic database to develop diagnostic, prognostic, and predictive models of cancer, including CRC. While at Sage Bionetworks, Dr. Guinney led an international consortium, resulting in the Consensus Molecular Subtypes of CRC. Subsequent work has focused on the translatability of these subtypes to inform programs in drug discovery and clinical care.



**KEITH HANIGAN**  
Vice President, Marketing and Strategy  
Natera

Keith Hanigan is currently the Vice President of Marketing and Strategy for Natera's oncology division. In this role Keith has been focusing on the development and commercialization of the Signatera molecular residual disease (MRD) test. Prior to joining Natera, Keith has 20+ years of experience focused on the delivery of advanced diagnostics and precision medicine to patients living with cancer.



**CHRISTOPHER HAQQ, MD, PhD**  
Chief Medical Officer  
Elicio Therapeutics

Dr. Haqq joined Elicio Therapeutics as Executive Vice President, Head of Research and Development and Chief Medical Officer in 2019. He brings over 20 years of drug development leadership across large and small biotechnology companies and across cell therapy, small molecule and biologics in large and small biotech settings. He has served as the medical monitor for oncology clinical trials and has worked closely with the US Food and Drug Administration and other global regulatory agencies. He has filed applications for investigational new drug applications, breakthrough therapy, priority medicines, special protocol assessments and their international equivalents, and marketing approval. Chris initially practiced as a medical oncologist and led a translational science laboratory as an Assistant Professor in the Division of Hematology/Oncology at the University of California, San Francisco.



**LIZ HEALY**  
Senior Partner, IBM  
and Stage 4 CRC Patient

Mrs. Healy is a Senior Partner of Strategy and Technology at IBM Consulting, the only major global consultancy that sits within a technology company, with principles grounded on open innovation, collaboration and trust. She works with clients to design, build and operate high-performing businesses. Mrs. Healy is currently battling advanced stage 4 metastatic colon cancer and is in active treatment on her second line of chemotherapy. She is blessed to be a Mom and has been a world traveler, foodie and athlete all her life recently completing the NYC Marathon while on chemo raising money for cancer survivorship support. She is a passionate patient advocate focused on finding ways to support others in treatment, increasing awareness for screening and finding ways to support research to save lives.



**J. RANDOLPH HECHT, MD**  
Professor of Clinical Medicine,  
David Geffen School of Medicine;  
Director of the UCLA Gastrointestinal Oncology Program  
University of California, Los Angeles

Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has led and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents.



**MANUEL HIDALGO, MD, PhD**  
Professor of Medicine and Chief of Hematology  
and Medical Oncology  
Weill Cornell Medicine

Dr. Manuel Hidalgo's career has focused on experimental therapeutics for GI cancers. In CRC, he has been involved in the development of PDX models, conduction of preclinical studies and clinical trials. His more recent work focused on the clinical development of the new CTLA-4 inhibitor botensilimab.



**ALAN HERBERT, MBChB, PhD**  
Founder  
InsideOutBio, Inc.

Dr. Herbert is originally from New Zealand where he earned his MBChB and PhD from the University of Auckland. He initiated his research on Z-DNA at MIT. Following this, his genetics research led to the publication of the first genome-wide association study on a human population in the journal Science. Following a period at Merck translating human genetics into therapies, Dr. Herbert founded the start-up InsideOutBio where he leads research to improve cancer therapy using approaches validated by human genetics.



**JENN HIGGINS**  
Vice President, Global Public Affairs  
Guardant Health

Since 2019, Jenn Higgins has led public affairs at Guardant Health, a leader in precision medicine and pioneer in liquid biopsy for cancer patients and survivors. Her work has focused on driving awareness of the value of liquid biopsy, particularly for colorectal cancer patients and survivors, in providing valuable information about how their cancer is changing and what targeted treatments might be most impactful. She is also shaping policy reforms in order to ensure that millions of Americans have access to new blood-based screening tests that can help to increase compliance with CRC screening.



**KATE HITCHCOCK, MD, PhD**  
Clinical Associate Professor, Department of  
Radiation Oncology  
University of Florida

Dr. Hitchcock is a Clinical Associate Professor in the UF Health department of radiation oncology. Dr. Hitchcock attended the University of Wyoming to earn her bachelor's degree in chemical engineering. She then pursued further higher education, earning a master's in mechanical engineering from the University of Maryland and a doctoral degree in biomedical engineering from the University of Cincinnati. She also earned her medical degree at the University of Cincinnati. Following her education, Dr. Hitchcock completed an internship at UF Health in the department of internal medicine and her residency in the department of radiation oncology. She is board certified with the American Board of Radiology, and a member of the American College of Radiation Oncology, American Society of Therapeutic Radiation Oncology, Florida Society of Clinical Oncology and Radiological Society of North America.



**STEVEN N. HOCHWALD, MD, MBA, FACS**  
Director, Cancer Center, Chief of Surgical Oncology  
Mount Sinai Medical Center

As a physician scientist, Dr. Hochwald has performed basic science and translational research in colorectal cancer and other GI malignancies for the past 25 years. Dr. Hochwald has served on the National Colorectal Cancer Roundtable with the goal of increasing screening for colorectal cancer in the United States. In addition, he has participated in writing the Operative Standards for Cancer Surgery for colorectal cancer together with other members of the American College of Surgeons. Dr. Hochwald's goals are to identify and evaluate novel signaling and metabolic pathways suitable for targeting with small molecule compounds as therapy in colorectal cancer.



**WILLIAM HOOS, MBA, MS**  
President  
H37 Institute

Mr. William (Willy) Hoos is an entrepreneur, executive, and venture leader in healthcare innovation. Among leading the H37 team, Mr. Hoos serves as President for the Jaime Leandro Foundation for Therapeutic Cancer Vaccines, is Vice President of Strategy with xCures, is a venture partner at Pilot Mountain Ventures, as well as Founder and CEO of NQ Oncology. In addition, he advises medical diagnostic, device, pharmaceutical and patient advocate organizations globally on product development and market strategy. His past clients include OncoPlexDx (acquired by NantOmics), Pancreatic Cancer Action Network, Skyline Diagnostics BV and Vanda Pharmaceuticals.



**PETER HOSEIN, MD**  
Associate Professor  
University of Miami

Dr. Hosein is a GI medical oncologist with a current research focus on targeting tumors with deficient homologous recombination as well as KRAS mutations. Dr. Hosein's clinical and translational work in HRD focuses on understanding the tumor-cell intrinsic as well as microenvironment factors that can facilitate responses to immunotherapy. Regarding KRAS-driven cancers, his approach is a combinatorial approach targeting downstream signaling in combination with immune checkpoint inhibition. Both lines of research are applicable to pancreas and colorectal cancers harboring either HRD or KRAS mutations.



---

**LEIGHTON HOWELLS**

Senior Vice President, Precision Biology Services  
RareCyte, Inc.

Mr. Leighton Howells has over 30 years of experience in developing, launching and commercializing new technology platforms for global markets. His technical and management career focused on the pioneer instrumentation and assays for High Throughput Screening, High Content Screening and highly multiplexed imaging to support pharmaceutical drug discovery/ development and diagnostics. With an extensive career at GE Healthcare in Life Sciences and Diagnostic business units, Mr. Howells held leadership positions in R&D, Operations and Commercial organizations, additionally leading the acquisition and integration of several high-performance imaging companies. Most recently, he was the Director of Operations, Pharma Services at NeoGenomics. Mr. Howells holds a bachelor's degree in biological sciences from the University of West England, Bristol.




---

**REGAN HUNEYCUTT**

Chief Development Officer  
Colorectal Cancer Alliance

Mrs. Huneycutt is a seasoned non-profit fundraising executive with extensive experience in diversified revenue generation to support organizational growth along with philanthropic relationship management. She serves as the Chief Development Officer for the Colorectal Cancer Alliance. Since joining the organization in 2016, Mrs. Huneycutt has led the team that has more than tripled the annual operating budget for the Alliance. She has worked in non-profit fundraising for 12 years and previously worked in print journalism, public relations and strategic communications for eight years.



---

**HANLEE JI, MD**

Professor  
Stanford University

Dr. Ji is a professor at Stanford University. Dr. Ji's clinical background is in medical oncology and clinical genetics. Their clinic is centered on gastrointestinal cancers and they run a research lab that is focused on studying the genome biology of metastatic colorectal and gastric cancers for the purpose of finding new targets.



---

**NIRAV JOSHI, MD**

Doctor of Medicine  
Mount Sinai Medical Center (Miami Beach, FL)

As a radiologist, Dr. Joshi works closely with medical oncologists, radiation oncologists, and oncologic surgeons in the accurate diagnoses and treatment planning for patients with cancer. In their South Florida community, they have a large cohort of CRC patients that aim to provide individualized care, establish meaningful radiologic testing for detection/ monitoring, and learn and then utilize novel technologies for therapy. As Dr. Joshi's institution expands their oncologic footprint with the opening of a new state of the art cancer center by 2025, they are actively looking to expand and grow in all facets of CRC diagnosis and treatment.





**HARTMUT JUHL, MD, PhD**  
Chief Executive Officer  
Indivumed GmbH

Dr. Hartmut Juhl is an entrepreneur, surgical oncologist and world-renowned researcher dedicated to the science of tissue quality and its application to precision medicine in cancer diagnostics and therapeutics. From 1987 to 1998, he worked as a surgical oncologist at the University Hospitals in Hamburg and Kiel, Germany, focusing on GIT-tract cancer. He then became Associate Professor at the Lombardi Cancer Center at Georgetown University in Washington DC, where he led a colorectal cancer research group. In 2002, he founded Indivumed GmbH to unravel the complexity of cancer and enable truly personalized medicine. Indivumed focuses on data- and AI-driven target and biomarker discovery, validation and therapeutic development based on a highly standardized global biospecimen collection as the basis for a unique multi-omics database of cancer.



**ADHAM JURDI, MD**  
Medical Director, Oncology  
Natera

Dr. Jurdi is a GI medical oncologist who practiced for 8 years at SUNY Upstate University, Syracuse VAMC and Austin Cancer Center before joining Natera in 2021 as medical director for GI oncology. Dr. Jurdi was an early adopter of ctDNA in CRC and had the privilege of driving this field forward in GI cancers with CRC being the poster child for ctDNA-guided, personalized management of CRC patients.



**MARK KAGANOVICH, PhD**  
Chief Executive Officer  
Tracer Biotechnologies

Dr. Kaganovich is the CEO and co-founder of Tracer Biotechnologies, a ctDNA liquid biopsy company specifically focused on longitudinal monitoring. The assay developed by Tracer has pan-cancer applicability. It has been utilized in the Lung and CRC exploratory settings. Prior to Tracer, he cofounded SolveBio, a software company used by BioPharma oncology trials for genomic data analysis and integration.



**PASHTOON MURTAZA KASI, MD, MS**  
Oncologist and Researcher  
Weill Cornell Medicine

Dr. Kasi is an oncologist and researcher focused on treating patients with colorectal cancer and other solid tumors using novel clinical trials and therapies. Dr. Kasi's focus has been on understanding the genomics and genetics of the underlying cancer and the person affected by it in order to help treat these cancers in a more personalized fashion. Their research and incorporation of other non-invasive tests like circulating tumor DNA (ctDNA) testing (often referred to as "liquid biopsies") allows them to help deliver this care better.



**PRAVIN T. P. KAUMAYA, PhD**  
Professor of Microbiology and Immunology and  
Director Brown Center  
Indiana University School of Medicine, Simon Comprehensive  
Cancer Center, Brown Immunotherapy Center

Dr. Kaumaya is currently the Professor of Microbiology and Immunology in the IU School of Medicine, Director of the Brown Center for Immuno-Oncology and Vaccine lab. Dr. Kaumaya was a Professor of Medicine at The Ohio State University, Director of the Division of Vaccine Research, and Peptide & Protein Engineering lab within the Medical Center and OSUCCC from 1989-2023. His work over the past 34 years has been in the field of B-cell vaccination developing innovative strategies to create paradigm shifts in developing combination cancer vaccines that would be safe and exhibit little or no toxicities. The main goal and focus of Dr. Kaumaya's research has been to develop vaccines to immune checkpoint molecules in syngeneic BALB/CT26 and C57Bl6/MC38 colon carcinoma mouse models. Present and future focus is to continue validating several combination immunotherapy.



**SANTOSH KESARI, MD, PhD**  
Director, Neuro-oncology; Chair and Professor, Department  
of Translational Neurosciences; Regional Medical Director,  
Research Clinical Institute, Providence Southern California  
Saint John's Cancer Institute/ Pacific Neuroscience Institute

Dr. Kesari has lead clinical trials in various types of brain tumors, including brain metastases, over the past 20 years. He is currently advising and participating in various early stage solid tumor clinical trials, including CRC, H&N, sarcoma, lung, breast, and melanomas using various modalities including targeted therapies, immunotherapy, personalized vaccines, and oncolytic viruses.



**SCOTT KOPETZ, MD, PhD, FACP**  
Professor  
The University of Texas MD Anderson Cancer Center

Dr. Kopetz is a physician-scientist, with a focus on colorectal cancer biology, biomarkers, and drug development, with a goal of advancing the field through team science, mentoring/ career development, and translational pursuits.



**ANGIE LAWRY**  
Senior Vice President of Marketing and Communications  
Colorectal Cancer Alliance

Under Mrs. Lawry's leadership, the Colorectal Alliance has seen tremendous growth in awareness and fundraising. Angie has been instrumental in developing and implementing strategies that have helped to increase visibility and engagement with the Alliance's key audiences. She has more than 20 years of experience in marketing and communications, with a focus on integrated communications strategy, marketing, publications, events, and programmatic resources. Her past roles include Director of Marketing/Communications at the Chief Executives organization, Director of Strategic Marketing for the Greater Washington Initiative and Vice President of Marketing and Communications at The Philanthropy Roundtable.



**HEINZ-JOSEF LENZ, MD, FACP**

Professor of Medicine and Preventive Medicine  
Keck School of Medicine of USC

The focus of Dr. Lenz's research is to identify predictive and prognostic biomarkers in colon cancer through large clinical trial databases to select patients who have the most benefit and least toxicity. Dr. Lenz has established a large preclinical model system to develop their own drugs targeting the tumor microenvironment of colon cancer taking advantage of their diverse patient population.



**CHRISTOPHER LIEU, MD**

Associate Professor, Associate Director for Clinical Research  
University of Colorado Cancer Center

Dr. Lieu is interested in resistance mechanisms to immunotherapy and targeted therapy in metastatic colorectal cancer. This includes the use of human immune system patient-derived xenografts to test rational combination strategies. In addition, some of Dr. Lieu's research is dedicated to the diagnosis and multidisciplinary management of early-onset CRC.



**BRIAN LICHTY, PhD**

Chief Executive Officer, Esphera SynBio Inc.;  
Associate Professor

Dr. Lichty has been developing cancer immunotherapies for over 20 years, typically using engineered viruses and more recently designer exosomes. On a personal note, Dr. Lichty's mother is a colorectal cancer survivor.



**DAVID LISKA, MD**

Colorectal Surgeon and Director of Sanford R. Weiss, MD  
Center for Hereditary Colorectal Neoplasia  
Cleveland Clinic

Dr. Liska, is a colorectal surgeon at the Cleveland Clinic. He holds the James Church, MD, and Edward J. DeBartolo, Jr. Family Endowed Chair in Colorectal Surgery and is an Associate Professor of Surgery at Cleveland Clinic Lerner College of Medicine. He serves as the Director of the Sanford R. Weiss, MD Center for Hereditary Colorectal Neoplasia and Fellowship Director for the Church-Sheetz Fellowship in Hereditary Colorectal Cancer Syndromes. He leads the Cleveland Clinic Center for Young-Onset Colorectal Cancer and the Colorectal Cancer Multidisciplinary Team Conference. His laboratory studies the biology of rectal cancer response to therapy with the goal of developing novel therapeutics that can overcome treatment resistance. His other research interests include hereditary and young-onset colorectal cancer and optimizing surgical outcomes through the implementation of enhanced recovery pathways.



**EMIL LOU, MD, PhD**

Associate Professor at the Masonic Cancer Center  
University of Minnesota

Dr. Lou is an Associate Professor at the Masonic Cancer Center of the University of Minnesota. His clinical interest includes whole-patient care of patients with early-onset/young-adult colorectal cancers, and his translational focus includes cell therapy and immunotherapy-based clinical trials for patients with CRC. His lab-based research program is centered on understanding the clinical cancer biology of solid tumors, with areas of expertise including structural, molecular, and cell biology of RAS-driven colorectal tumors. A principal strategy of this work is to focus on uncovering the crucial roles of intercellular communication in inducing tumor heterogeneity and emergence of chemotherapy resistance, an approach referred to as 'Subcellular Oncology'.



**MELISSA LYNCH, SHRM-SCP**

Chief People Officer  
Colorectal Cancer Alliance

Ms. Lynch is a Senior Certified Professional in Human Resources Management and Services. Through her role as the Alliance's Chief People Officer, she works with staff on setting and achieving goals, implementing organizational leadership and developmental strategies, building a dynamic team, and supporting strategic alignment of diversity, equity and inclusion efforts. Ms. Lynch also leads the volunteer strategy and efforts at the Alliance, building our Nation of Allies in supporting and driving community, fundraising and mission. She has previously led strategy, business, and teams with Apple Inc., Gymboree and The Walt Disney Company.



**AMY LOW**

Managing Director, Fellowships and Nonprofit Media  
at Emerson Collective and Colorectal Cancer Alliance  
Board of Directors Member

Ms. Low is a managing director with Emerson Collective, an organization working to advance progress across a range of priority areas, including cancer research. She was diagnosed with Stage IV CRC in July 2019 and is actively searching for a new trial. She's also the proud mom of her two children -- Connor and Lucy -- and is the author of "The Brave In-Between," a book published by Hachette coming out on June 4, 2024.



**CHARLES MANNING, PhD**

Department of Cancer Systems Imaging,  
Division of Diagnostic Imaging  
The University of Texas MD Anderson Cancer Center

Dr. Manning is a chemist with a background in radiochemistry, medicinal chemistry and imaging science; today much of his lab focuses on radionuclide theranostics and drug development. Over his career, the majority of Dr. Manning's research efforts have prioritized CRC, dating back to his days at Vanderbilt University where he co-led Project 2 of Vanderbilt's GI SPORE (PI Bob Coffey) with Jordan Berlin. This CRC-centric work led to the Manning lab's discovery of the first potent and selective small molecule glutamine transport inhibitor (V-9302), which is progressing towards clinical studies, with key emphasis on CRC. Dr. Manning has continued to devote much of his effort to image and treat patients with CRC, and has developed strong collaborations with Scott Kopetz and colleagues of the MD Anderson GI program.





**JOHN L. MARSHALL, MD**  
Director, The Ruesch Center for the Cure of GI Cancers; Chief Medical Officer, Lombardi Comprehensive Cancer Center Medstar/Georgetown

Dr. Marshall is an internationally recognized expert in new drug development for GI cancer, with expertise in phase I, II, and III trial design, and has served as Principal Investigator for over 100 clinical trials. In 2009, he established the Otto J Ruesch Center for the Cure of GI Cancers focused on improving the lives of GI cancer patients through innovative research, personalized medicine, and focused advocacy. In 2015, Dr. Marshall established and directed the Precision Oncology Alliance to study the impact of molecular profiling on cancer research, value and outcomes. He currently is serving as the Oncology CMO for Indivumed. In 2020, he and his wife published "Off Our Chests, A Candid Tour Through the World of Cancer." In 2022, he became the inaugural Physician Executive Director of the MedStar Washington DC Integrated Hematology Oncology Division.



**GABRIEL MORRIS**  
Chief Financial Officer  
Immix BioPharma, Inc.

Mr. Gabriel Morris is the Chief Financial Officer of Immix BioPharma, Inc. Mr. Morris has been managing partner of Alwaysraise LLC, a life sciences advisory and investment firm based in San Francisco, since founding. Prior, Mr. Morris was the interim Chief Financial Officer of Zap Surgical Systems, a brain radiosurgery company, where he completed a growth equity financing round. Prior, Mr. Morris led cross-border mergers & acquisitions transactions at Goldman Sachs and other global investment banks for more than a decade, where he participated in greater than \$50 billion in completed transactions.



**GOVINDARAJAN NARAYANAN, MD**  
Chief of Interventional Oncology  
Baptist Health South Florida

Dr. Narayanan is an interventional radiologist at two of Baptist Health South Florida's service lines: Miami Cardiac and Vascular Institute, and Miami Cancer Institute, where he has been named chief of interventional oncology. Most recently, he served as medical director of Interventional Radiology at University of Miami Hospital and Clinics, and as the founding chairman of the Department of Interventional Radiology at the University of Miami Miller School Of Medicine, where he also served as a professor of interventional radiology and of urology. Dr. Narayanan's primary clinical research interests include pancreatic, liver and colon cancer.




**KIM NEWCOMER**  
Director of Volunteers  
Colorectal Cancer Alliance

Mrs. Newcomer is the Director of Volunteers for the Colorectal Cancer Alliance and a 15-year stage IV rectal cancer survivor. She serves on the Boehringer Ingelheim's Global Patient Advisory Board, Colorectal Cancer Patient Steering Committee, Pfizer Patient Centric CRC Steering Committee, and Novartis Patients Insights Panel. In addition, she is a Stakeholder Advisory Board Member for the THRIVE-MCRC study, serves as a mentor for the AACR Scientist Survivor Program, and managed the Never Too Young Advisory Board. Mrs. Newcomer has published more than 30 abstracts that demonstrate the value and use of patient-reported outcome survey data. In her current role as Volunteer Director, she trains and empowers volunteers to provide support, raise awareness, and fund critical research at the grassroots level.



**MIKA NEWTON**  
Chief Executive Officer  
xCures

Mr. Newton is the CEO of xCures, which provides AI-powered data aggregation and decision support technology for CRC and other cancer patients. He has worked on technology to support health economics, market access, guideline development, policy analysis, literature review and synthesis, and health technology assessment, including CRC and other diseases. He has a background in biotechnology and executive management.



**PETER J. O'DWYER, MD**  
Professor of Medicine, University of Pennsylvania; Co-Chair,  
ECOG-ACRIN Cancer Research Group  
University of Pennsylvania; ECOG-ACRIN

Dr. O'Dwyer is the PrECOG, LLC Board of Managers Chair and CEO. He is a medical oncologist at the University of Pennsylvania, where he holds an appointment as Professor of Medicine. His research focus is in the area of novel therapy development, primarily in pancreatic and colorectal cancers. Since 2017, he has served as Group Co-Chair for ECOG-ACRIN Cancer Research Group, where he also leads the GI Cancer Committee.



**KIMMIE NG, MD, MPH**  
Associate Chief, Division of Gastrointestinal Oncology  
Dana-Farber Cancer Institute

Dr. Ng is Associate Chief of the Division of Gastrointestinal Oncology at Dana-Farber Cancer Institute, and an Associate Professor of Medicine at Harvard Medical School. She serves as Co-Director of the Colon and Rectal Cancer Center and the Director of Translational Research in the division. She is also the Founding Director of the Young-Onset Colorectal Cancer Center at Dana-Farber. Her research focuses on identifying dietary, plasma, and molecular predictors of improved survival in patients with colorectal cancer, with a special interest in the vitamin D pathway, the microbiome, and young-onset colorectal cancer. As Director of Translational Research, she oversees the Gastrointestinal Cancer Biobank and facilitates translational research projects with academic and industry collaborators. She is also involved in the design and conduct of clinical trials, and has served as Principal Investigator of several national multi-center randomized trials.



**MICHAEL PISHVAIAN, MD, PhD**  
Associate Professor  
Johns Hopkins

Dr. Pishvaian is a translational oncologist, who has strived to provide novel therapies for patients, particularly in the areas of pancreatic cancer and refractory colorectal cancer. He has been a Phase I program leader for most of his career, focusing trials in the area of precision medicine, with a special focus on therapy targeted towards homologous recombination DNA repair deficient tumors.



**JENNY PERMUTH, PhD, MS**  
Vice Chair of Research, Department of  
Gastrointestinal Oncology  
Moffitt Cancer Center

Dr. Permuth currently serves as the first Vice Chair of Research in Moffitt's Department of Gastrointestinal Oncology where she diagnoses and treats a significant number of individuals and families with or at risk for colorectal cancer each year. Dr. Permuth's background is in clinical genetics, molecular biology, and epidemiology. Colorectal cancer has impacted Dr. Permuth's family, and she is dedicated to reducing the burden of this disease in partnership with the scientific community and advocacy groups.



**KANWAL RAGHAV, MD**  
Associate Professor  
The University of Texas MD Anderson Cancer Center

Dr. Raghav is an Associate Professor in the Department of Gastrointestinal Medical Oncology with clinical and research efforts centered on tumor biology and developmental therapeutics in colorectal cancer. Dr. Raghav's research focuses on predictive biomarkers, ctDNA applications, immunotherapy, HER2-selection, and antibody-conjugates in colorectal cancer. He believes that team science and revolutionary ideas can truly change the status quo and further precision care for patients with colorectal cancer.



**ILYA RACHMAN, MD, PhD**  
Chief Executive Officer  
Immix Biopharma, Inc.

Dr. Rachman is a physician/scientist and former community clinical faculty at UCLA. He received both his MD and PhD from the University of Illinois, and his MBA from UCLA Anderson. Dr. Rachman founded a Clinical Research organization that conducted clinical trials of pharmaceutical drugs, and is also currently the CEO of Immix Biopharma, Inc. He has completed several clinical trials as a Principal Investigator and developed strong relationships in the clinical research industry.



**CHETAN RAJADHYAKSHA, MD**  
Chairman, Department of Radiology  
Mount Sinai Medical Center

Dr. Rajadhyaksha serves as the Chairman of Radiology at Mount Sinai Medical Center in Miami Beach, where he oversees imaging and radiation oncology services ensuring quality patient care. With over 15 years of experience, Dr. Rajadhyaksha leverages his proficiency in nuclear medicine, including the use of PET/CT and other advanced diagnostic imaging, to aid in the management of colon cancer patients. His expertise in interpreting complex scans, radiotherapy, and collaborating with oncology teams enables customized care for colon cancer patients at Mount Sinai.



**GOPAL RAMACHANDRAN, MD, PhD**  
Chief Scientific Officer  
TracerDx

Dr. Ramachandran is the CSO and co-founder of Tracer Biotechnologies, a ctDNA liquid biopsy company specifically focused on longitudinal monitoring. The assay developed by Tracer has pan-cancer applicability. It has been utilized in the Lung and CRC exploratory settings. Prior to Tracer, he was the CTO at Wellframe, a digital health company used by insurance companies for the management of chronic disease.



**ADAM RENSLO, PhD**  
Professor  
University of California, San Francisco

Dr. Renslo's lab is engaged in chemical biology and medicinal chemistry with a focus on labile iron in biology and disease. Their interest in CRC stems from recent findings that KRAS mutations elevate labile iron in cancer cells and mouse xenograft models, as determined with novel chemical tools our lab has developed. They have also invented a chemical strategy to activate therapeutic small molecules in the presence of labile iron, and with collaborators demonstrated this approach in multiple xenograft models of KRAS mutated cancers.



**JIM REICHBACH**  
Global Banking & Securities Sector Leader at Deloitte  
and Patient Advocate

Mr. Reichbach is the Global Banking and Securities leader, with responsibility for setting global strategy, deployments and coordination of global network. Since joining Deloitte more than 20 years ago from the industry, he has worked with many of the leading financial services companies in the world. His consulting engagements have focused on the banking, investment management and securities industries, as well as selected engagements in the insurance industry.



**MONICA RIEDESEL**  
Senior Coordinator of Volunteers  
Colorectal Cancer Alliance

Mrs. Monica Riedesel joined the Colorectal Cancer Alliance as a Community Engagement Intern in October 2022 and now serves as the Senior Coordinator of Volunteers. As part of the Alliance's Volunteer Team, Mrs. Riedesel recruits for the Alliance's #NationofAllies and supports nearly 2,000 existing Alliance volunteers in their efforts toward ending colorectal cancer in this lifetime. She has seen the impact of colorectal cancer firsthand when she was a child and her uncle survived colon cancer in his 30s and then again in 2021, when her step-father was diagnosed with colon cancer. Mrs. Riedesel is grateful to, now, interact directly with those impacted by colorectal cancer, to make a positive impact in their lives and communities.





**DESIRÉE RUITERS**  
Associate Director, Patient Alliances  
Taiho Oncology, Inc.

Mrs. Ruiters currently serves as the Associate Director of Patient Alliances at Taiho Oncology, Inc. Prior to joining Taiho Oncology, Inc., she worked at The Aplastic Anemia and MDS International Foundation, where she held the roles of Senior Director of Development, Corporate Relations Officer/ Director of Development and Database Manager.



**ALIASGER SALEM, PhD**  
Bighley Chair and Professor of Pharmaceutical Sciences  
University of Iowa

Dr. Salem is the Associate Vice President for Research and Bighley Chair and Professor of Pharmaceutical Sciences. His research interests are focused on the rational design of novel drug and gene delivery systems, and on the development of vaccines that stimulate potent antigen-specific immune responses against CRC. His laboratory applies microfabrication techniques and conjugation chemistry to develop novel drug and gene delivery systems and to target colorectal cancer. His research group is exploring the synergistic application of polymer particle technology, oligonucleotides, modified RNA, adenoviruses, and small molecules for generating sustained stronger immune responses against CRC.



**DAVID RUSSO, MBA**  
Executive Director  
Cheeky Charity

Mr. Russo is a healthcare professional that creatively blends technical skill, strategic marketing, and public health advocacy. Starting his career at Siemens Healthcare Diagnostic, he developed a foundation in engineering before getting promoted into global marketing and project management roles. Leading Cheeky Charity, a non-profit focused on colorectal cancer awareness in the LGBTQ+ community, Mr. Russo has initiated key projects like the social media #cheekychallenge and local grassroots “March Your Butt” campaign in Palm Springs, California. His commitment to this cause is personal, driven by family experiences with colorectal cancer and his own pre-cancerous colorectal health challenges at 32 years old. His work at Cheeky Charity is marked by a focus on early detection and prevention, showcasing his ability to address complex health issues and inspire teams.



**GINO R. SANTORIO**  
President and Chief Executive Officer  
Mount Sinai Medical Center

With over 17 years of executive health care experience, Mr. Gino R. Santorio serves as the President and CEO of Mount Sinai Medical Center. Recognized locally and nationally, he has broad experience leading health systems in the for profit, not for profit, public and private sectors. Mr. Santorio is a Fellow of the American College of Healthcare Executives. Acknowledged as a “Healthcare Leader Under 40” by Becker’s Hospital Review, he also serves as the Chair of the Florida Hospital Association.



**MICHAEL SAPIENZA**  
Chief Executive Officer  
Colorectal Cancer Alliance

Mr. Sapienza is the Chief Executive Officer of the Colorectal Cancer Alliance, the largest colorectal cancer advocacy group in the country. He has become an expert and trusted voice on the topics of colorectal cancer prevention, patient care, and medical research. Mr. Sapienza is a member of The Ruesch Center for the Cure of GI Cancer's Advisory Board at Georgetown University, was appointed to the President's Cancer Panel and NCCRT's 2021 Steering Committee, and is a recipient of the David Jagelman, MD Award for advocacy in Colorectal Cancer Awareness by the American Society of Colon and Rectal Surgeons; the Public Service Award from the Society for Surgery of the Alimentary Tract; and the Champion Award from Preventing Colorectal Cancer and the Luminary Award from OncLive and The Ruesch Center for his lifetime commitment to improving the lives of patients affected by gastrointestinal cancer.



**NICOLE SCHROEDER**  
Director, Patient Advocacy  
Seagen Inc.

Nicole Schroeder is the Director, Patient Advocacy for Seagen Inc., a global biotechnology company dedicated to revolutionizing cancer care through the development of transformative therapies that make a meaningful difference in people's lives. With almost two decades of experience in healthcare and advocacy, she is responsible for incorporating the CRC patient experience into all aspects of planning and execution at Seagen, while cultivating long-term partnerships between the company and the CRC patient advocacy community. Her experience spans community pharmacy, academic medical centers, non-profit professional societies, and the biotech industry.



**STEPHEN P. SCHOENBERGER, PhD**  
Professor  
La Jolla Institute for Immunology

Dr. Schoenberger is a Professor in the Laboratory of Cellular Immunology at the La Jolla Institute for Allergy and Immunology, Adjunct Professor of Medicine in the Division of Hematology and Oncology at the UCSD Moores Cancer Center, and co-director of the San Diego Center for Personalized Cancer Immunotherapy.



**KENNETH SHAPIRO**  
Co-Founder  
BreakBio Corp

Mr. Shapiro is a former serial entrepreneur and now advises successful entrepreneurs, founders and CEOs of rapidly growing companies on their personal financial issues related to their families, strategic business exit planning and inter-generational wealth planning. His wife Patricia was diagnosed with rectal cancer in 2017. Mr. Shapiro dug deeply into colorectal cancer, he traveled the world meeting the very top doctors, researched every appropriate clinical trial he could find and convinced his wife's doctors at MSK to combine unique experimental treatments that he pulled together from collaboration between cross-institutional specialists. This helped, but was not enough. From this he learned that beyond front line chemo there is no very effective treatment for metastatic colorectal cancer. Mr. Shapiro became determined to make a difference and achieve success against this cancer in his lifetime, thereby leading him to Co-Found BreakBio.



**SUNIL SHARMA, MD, FACP, MBA**

Physician in Chief Professor and Division Director, Applied Cancer Research and Drug Discovery Translational Genomics Research Institute (TGen)  
TGen

Dr. Sharma is the Physician-In-Chief at Translational Genomics (TGen) in addition to Deputy Director of Clinical Sciences and Professor and Division Director of Applied Cancer Research and Drug Discovery. He is also a Professor of Medicine at City of Hope (COH). His interest is conducting drug discovery and translational research on novel therapies for cancer. Currently, the main focus of his drug discovery programs are centered on epigenetic and immune pathways.



**JOHN PAUL Y.C. SHEN, MD**

Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center

Dr. Shen is a physician-scientist with a scientific background in chemical biology, functional genomics, and systems biology leading a lab team of computational, experimental, and clinical scientists studying the genomics and transcriptomics of colorectal cancers. They combine knowledge from testing model systems, molecular profiling of CRC tumors, and have built a software system to capture clinical information from the over 3,000 patients with CRC treated at MDA every year so we can learn from patients not on clinical trials. With these sources of data, they are trying to move away from the historical one-size-fits-all approach to chemotherapy to precision oncology. Active projects include high-throughput double gene knockout with CRISPR-cas9 to identify new synergistic drug combinations, investigating interaction of tumor cells with tumor microenvironment (TME) using the largest cohort of CRC patients profiled with single cell RNAseq, and utilizing circulating tumor DNA to identify minimal residual disease.



**SANDRA S. SHAW, MBA, BS**

Senior Director, Patient Advocacy and Engagement  
Mirati Therapeutics

Sandra Shaw has an extensive career in industry and advocacy. As part of Merck's Medical Affairs team in Advocacy and Professional Affairs, she delivered and implemented IME/CME, advocacy, and professional relations strategies and supported innovative educational initiatives for physicians, patients, and caregivers. Her work included lung cancer, melanoma, breast, head and neck, colorectal cancer and other GI cancers. Sandra followed her passion for cancer advocacy, to become the Director of the Lung Cancer Registry for the GO2 Foundation. She was able to advance patient-centered research and knowledge of patient reported outcomes in lung cancer patients. Sandra held the position of Vice-President of Strategic Alliance and Patient Engagement Strategy at MJH Life Sciences, where she led partnership and educational efforts that included colorectal cancer and other GI cancers with oncology patient advocacy organizations and industry for CURE Media Group (Cancer Updates, Research and Education).



**XILING SHEN, PhD**

Chief Scientific Officer  
Xilis, Inc, Terasaki Institute for Biomedical Innovation

Dr. Shen is the Chief Scientific Officer and Professor of the Terasaki Institute for Biomedical Innovation and the founder and former Chief Executive Officer of Xilis Inc, a precision medicine startup that raised \$89M Series-A. He was formerly the Hawkins Professor and Director of the Woo Center for Big Data and Precision Health at Duke University. He was the Steering Committee Chair of the NCI Patient-Derived Model of Cancer Consortium, Co-Chair of the NCI Tissue Engineering Consortium, Cancer Track Chair of Biomedical Engineering Society 2019, and leader of the Chan-Zuckerberg gut-brain axis project.



**ARDAMAN SHERGILL, MD**  
Assistant Professor of Medicine  
University of Chicago

Dr. Shergill is a medical oncologist with expertise in colorectal, appendix and pancreatic cancers. Her research focuses on clinical trials using targeted therapies for gastrointestinal cancers, use of circulating tumor DNA and patient reported outcomes. She also serves as the executive officer for the gastrointestinal cancers committee at the Alliance for Clinical Trials in Oncology, a National Cancer Institute funded oncology research organization.



**ROY DE SOUZA, ME, MBA**  
Founder and Chief Executive Officer  
BreakBio Corp

Mr. de Souza is solving a big problem of our lifetimes: curing cancer, starting with colorectal. He uses AI Drug Discovery PER PATIENT, to design and manufacture 30 new drugs (peptides) per patient. Mr. de Souza received a masters in Engineering at Oxford, an MBA from the Kellogg School and worked for Elon Musk's first company. He founded ZEDO Inc. that became the 3rd largest ad server in the world and used AI to determine which user sees which ad. He sold ZEDO to Warner Bros Discovery, the world's largest media company which owns CNN and HBO. He became determined to get to cures when his wife was diagnosed with colon cancer in 2017. She later passed away. He has 3 young children and is moving to Miami.



**MAX SKLAR, MBA**  
Vice President of Development  
Mount Sinai Medical Center

Mr. Sklar currently holds the position of Vice President of Development at Mount Sinai Medical Center Foundation, where he leads the organization's development team, creating strategies that will increase the donor base and overall contributions to address the needs of the Medical Center. Mr. Sklar serves as the primary liaison to the Foundation Board, as well as major donor fundraising. With a career spanning the public sector and real estate development, he brings a forward-thinking approach to expanding the Foundation's donor base.



**JUSTIN STEBBING, MD, PhD**  
Editor-in-Chief  
Oncogene

Dr. Stebbing is Editor-in-Chief of Oncogene and was the UK's first NIHR Translational Research Professor in Oncology. He originally trained in Oxford then Johns Hopkins, and currently works in London and Cambridge, combining laboratory research and patient care. He is very excited to be with you in Miami!





**SHARON L. STEIN, MD, FACS, FASCRS**  
Adjunct Professor  
Case Western Reserve School of Medicine

Dr. Stein is a colon and rectal surgeon who directed the University Hospitals/Case Medical Center Surgical Outcomes Center (University Hospitals Research in Surgical Outcomes and Effectiveness). She has over 150 published papers, chapters and is an internationally known speaker. She works with a multidisciplinary team studying the role of radiomics on predictive factors of MRIs on treatment effects for patients with rectal cancer.



**CHRISTOPHER THANOS, PhD**  
Cofounder and Chief Executive Officer  
Actym Therapeutics, Inc.

Dr. Thanos is the President, CEO, and Cofounder of Actym Therapeutics, a venture-backed biotech focused on developing novel immunotherapies intended to transform the treatment of cancer. Actym's microbial-based platform selectively delivers multiplexed genetic payloads to tumors after intravenous dosing, utilizing a non-viral mechanism of action. Prior to Actym, he was Head of Biotherapeutics Discovery at Halozyme, Head of Protein Engineering at Sutro Biopharma and a co-founder of Catalyst Biosciences. He was a National Cancer Institute Postdoctoral Fellow under Professor Jim Wells at UCSF and Sunesis Pharmaceuticals, Inc. Dr. Thanos earned a Ph.D. from UCLA where he was a NIH Chemistry/Biology Interface Predoctoral Fellow. He is an inventor on 33 issued and multiple pending patent applications in the areas of biological and cellular therapeutics, and a first author of multiple peer-reviewed articles in top-tier scientific journals.



**JAMEE TELFORD**  
Director of Industry Giving  
Colorectal Cancer Alliance

Ms. Telford joined the Colorectal Cancer Alliance staff in 2020 and now serves as the Director of Industry Giving. She brings a passion for raising awareness about colorectal cancer and supporting patients and families after losing her father to colon cancer in 2014. She focuses on growing the Alliance's Industry partnerships portfolio that includes over 150 companies ranging from start-up to large scale pharmaceutical companies, medical device companies, diagnostic laboratories, to screening test products. She works collaboratively with the Alliance's Leadership Team to fundraise and attain the Alliance's revenue goals. Prior to working at the Alliance full-time, Jamee volunteered for the organization, launching the DC Allies team and serving as the DC ScopeltOut 5k event co-chair in 2020 and 2021.



**MARSHALL THOMPSON, PhD**  
President  
The Rare Cancer Research Foundation

Dr. Thompson is a multidisciplinary scientist, software engineer, and business leader with a strong interest in applying cutting-edge software practices to genomic-scale biological problems. As President of the Rare Cancer Research Foundation, Dr. Thompson is focused on building tools and infrastructure that empower patients and researchers, accelerating discovery and deployment of novel therapeutic options in personalized oncology.



**JERRY J.K. TILLERY, MBA, MHA, FACHE**  
Chief Impact Officer  
Colorectal Cancer Alliance

Mr. Tillery serves as the Chief Impact Officer of the Colorectal Cancer Alliance. He is an accomplished non-profit healthcare executive with over 20 years of experience in operations, business development, sales, marketing, and patient/customer service. Jerry is passionate about instilling a shared sense of purpose, empowering individuals, and creating high-performing teams. His past roles include Division Vice President, Chief Recruitment Executive, Chief Collections Executive and Regional Chief Executive Officer for the American Red Cross and Vice President of Operations at Wellstar Health System. Jerry is a Fellow of the American College of Healthcare Executives.



**WENYI WANG, PhD**  
Professor of Bioinformatics and Computational Biology  
The University of Texas MD Anderson Cancer Center

Dr. Wang is a Professor of Bioinformatics and Computational Biology and Biostatistics at the University of Texas MD Anderson Cancer Center. She received her PhD in biostatistics from Johns Hopkins University, and her postdoctoral training in statistical genomics at UC Berkeley with Terry Speed and in genome technology at Stanford with Ron Davis. Dr. Wang's research includes significant contributions to statistical bioinformatics in cancer, including MuSE for subclonal mutation calling, DeMixT for transcriptome deconvolution, and more recently, a pan-cancer characterization of genetic intra-tumor heterogeneity in subclonal selection, as well as a pan-cancer biomarker identification through integrative deconvolution of transcriptomic/genomic data.



**ALAN VENOOK, MD**  
Madden Family Distinguished Professor of Medical Oncology and Translational Research; Shorenstein Associate Director for Program Development at the Helen Diller Family Comprehensive Cancer Center  
University of California, San Francisco

Dr. Venook has been involved in either early or definitive studies of almost every agent currently in use in the disease. He served on DSMB's for studies from bevacizumab to Sotarasib; chaired, presented and was lead author on CALGB/SWOG 80405; and was co-author on dozens of translational papers. Dr. Venook chaired the GI Committee within the Alliance, served as Associate Editor of JCO and has served as vice-chair of the NCCN Colorectal Cancer Guideline panel since its inception.



**JOE WHALEN, MBA**  
North Glen Advisors and Colorectal Cancer Alliance  
Board of Directors Member

Mr. Whalen has more than 25 years of experience in the healthcare industry leading and supporting transactions involving licensing, acquisitions, and alliances. He was among the first 20 employees when he joined Horizon in 2010 and has led or supported many of Horizon's acquisitions since that time helping to grow Horizon into a publicly-traded company with a market capitalization of greater than \$20 billion, over 1,700 employees, and net sales approaching \$3 billion per year. He played a leadership role in the strategy and execution of Horizon's recent acquisition of Viela Bio for \$3 billion. Mr. Whalen and his wife Jen became involved with the Colorectal Cancer Alliance after losing Jen's younger brother Ryan to this terrible disease.



**JASON WILLIS, MD, PhD**

Assistant Professor  
The University of Texas MD Anderson Cancer Center

Dr. Jason Willis is a GI medical oncologist and clinical investigator at University of Texas MD Anderson Cancer Center. With expertise in clinical cancer genetics/genomics, his work focuses on the development of novel cancer prevention strategies for individuals with hereditary colorectal cancer syndromes and elucidating genomic drivers of racial/ethnic disparities in early-onset CRC.



**ZHAOHAI YANG, MD, PhD**

Associate Professor and Director of GI/Liver Pathology  
University of Pennsylvania

Dr. Zhaohai Yang is a gastrointestinal surgical pathologist who trained at both UAB and MSKCC. He recently served as the Director of GI/Liver Pathology at Penn Medicine. Dr. Yang's expertise is to identify the tumor tissue, characterize its morphologic features, select and analyze relevant biomarkers, and correlate the biomarker expression with other parameters of the tumor and/or patient including clinical presentation, disease progression, prognosis, and treatment response. Dr. Yang has worked with clinical collaborators on the utility of liquid biopsy in colorectal cancer, and showed that circulating tumor cells were associated with tumor burden, advanced stage, and CEA levels, though heterogeneity does occur. Thus assessment of circulating tumor cells using liquid biopsy may be a valuable alternative to invasive tissue biopsy for colorectal cancer.



**JOHN WOERNER**

Board of Directors Member  
Colorectal Cancer Alliance

Mr. John Woerner is a Stage IV rectal cancer survivor who navigated the standard of care and clinical trials world before getting to NED. He knows that the path to better treatments and a cure lies in clinical trial matching and participation. Navigating the clinical trial process as a patient is far more complex and challenging than it should be - even for a well-educated former Fortune 250 executive like himself. To help accelerate and simplify that path to better treatments and a cure, Mr. Woerner has started a fund to support better clinical trial engagement and navigation with the Colorectal Cancer Alliance. In addition, Mr. Woerner is active on the Alliance's board, is focused on clinical trial advancement, keeps abreast of trial developments as an ASCO and ESMO patient advocate, and directly coaches and mentors individual patients weekly as they navigate clinical trials.



**CASSIAN YEE, MD**

Professor, Department of Melanoma Medical Oncology,  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center

Dr. Cassian Yee has pioneered a form of adoptive cellular therapy known as endogenous T cell (ETC) therapy that has proven highly effective for patients with cancer. This approach yields memory T cells of defined specificity and is well-suited for the treatment of patients with colorectal cancer. Combined with this is his tumor immunopeptidome platform, which includes several CRC targets for ETC and TCR-based therapy of patients with CRC and other cancers.





**ELCIN ZAN, MD**

Assistant Professor of Radiology  
Weill Cornell Medicine

Dr. Elcin Zan is a nuclear medicine physician and radiologist with a focus on Radiopharmaceutical Theranostics at Weill Cornell Medicine. Her research interest is in Radiolabeled Fibroblast activation protein (FAP) in colorectal cancer diagnosis and therapy combinations.

**Notes**























Project  
**Cure**  
CRC